Inhaled Nanomedicines: Companies, Startups & Research

Named corporate participants include Insmed, Translate Bio and Pharmosa Biopharm Inc.; CanSino-linked entities also appear among patent holders. Insmed has 5 listed patents in the window, while Translate Bio and Pharmosa Biopharm Inc. each have 5 and 4, respectively. These records identify active organizations, but do not establish that every listed company currently markets an inhaled nanomedicine.

Plumestars Srl is a named startup, with 2 documents in the window; the dataset lists 16 startups overall. Its work concerns a patented inhalable powder composition that embeds nanoparticles in microparticles for lung delivery of therapeutic or diagnostic compounds. The available information identifies its approach, but does not support a comparative ranking of startup prospects.

Chinese Academy of Sciences CAS has 48 documents in the window, while Sun Yat Sen University and Soochow University each have 29. CAS research includes inhaled mRNA lipid nanoparticles and liposomes; Sun Yat Sen University studies collagenase-coated polymeric nanoparticles for pulmonary fibrosis; Soochow University works on nebulized lipid nanoparticles for mRNA delivery.

Funding data lists $17,497,402 across 25 grants since 2020, alongside 21 funding rounds totaling $2,153,039,993. The round total includes broad institutional financing records, so it is not a clean measure of investment dedicated only to inhaled nanomedicines. The latest listed company financing is Ethris’s $34,918,762 debt and equity round in September 2026.

Cansino (Shanghai) Biological Research Co., Ltd. leads the listed patent holders with 7 patents. Insmed and Translate Bio each have 5; the Board of Regents of the University of Texas System, the Trustees of the University of Pennsylvania and Pharmosa Biopharm Inc. each have 4. These are holder counts in the patent data, not measures of patent quality or commercial impact.

No: reported patent growth is -57.1%, with 223 patents in the 24-month window. By contrast, publications reached 699 in the latest year, with reported growth of 1.0%. The indicators suggest research output is holding relatively steady while recent patent activity has fallen; they do not, by themselves, show why the two trends differ.

Recent developments include EV-liposome hybrid vesicles for inhaled nintedanib delivery in pulmonary fibrosis, reported in September 2026, and carnosine-loaded liposomes studied for acute lung injury that same month. In August 2026, researchers also described polymer nanoparticles with gradient protonation to address mucus and biofilm barriers. These studies highlight aerosol stability, local delivery and tissue penetration as active design targets.

The listed approaches are lipid carriers (845 documents), polymeric carriers (289), nano-enabled powders (233), inorganic nanocarriers (115) and surfactant-based carriers (107). Lipids and polymers support payload encapsulation and tunable release; powders focus on aerosol delivery; inorganic and surfactant-based systems offer other material properties. Each approach must balance delivery performance with stability, safety and manufacturability.

The listed applications include lung cancer (391 documents), genetic lung diseases (361), asthma and airway inflammation (285), respiratory infections (195) and pulmonary vaccination (99). These areas use local delivery to address distinct therapeutic needs, from nucleic-acid delivery to antimicrobial treatment. The document counts indicate research activity, not the number of approved treatments or clinical successes.

The field remains research-led: the data lists 814 research organizations and 44 clinical-trial records overall, alongside 223 patents in the 24-month window. That activity shows work across discovery, intellectual property and clinical investigation, but does not establish broad clinical adoption. Translation still depends on reliable aerosol performance, lung deposition, safety and reproducible manufacturing.